<https://rdf.molmedb.upol.cz/reference/ref943> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM18018>,
		<https://rdf.molmedb.upol.cz/interaction/membrane46>,
		<https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://rdf.molmedb.upol.cz/interaction/method71>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.7b00410"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/pmid> "28530802"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Felts AS, Rodriguez AL, Blobaum AL, Morrison RD, Bates BS, Thompson Gray A, Rook JM, Tantawy MN, Byers FW, Chang S, Venable DF, Luscombe VB, Tamagnan GD, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA.: Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. J Med Chem, Volume 60 (12), 2017"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1009215> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref943> .
<https://rdf.molmedb.upol.cz/interaction/int1029930> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref943> .
<https://rdf.molmedb.upol.cz/interaction/int1029929> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref943> .
<https://rdf.molmedb.upol.cz/interaction/int1009216> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref943> .